Skip to main content

Advertisement

SpringerLink
Log in

Chemotherapeutic agents in low noncytotoxic concentrations increase immunogenicity of human colon cancer cells

  • Original Paper
  • Published:
Cellular Oncology Aims and scope Submit manuscript

Abstract

Background

We have recently reported that chemotherapeutic agents in ultra low noncytotoxic concentrations may block the ability of tumor cells to suppress functional activation of dendritic cells (DCs).

Methods

HCT-116 human colon cancer cells were treated with 0.5 nM paclitaxel (PAC) or 2 nM doxorubicin (DOX) with the aim of defining the immunogenic changes induced by ultra low noncytotoxic concentrations of antineoplastic chemotherapeutic agents. Genetic alterations were screened by DNA microarray that revealed increased expression of genes involved in antigen processing and presentation, including the heat-shock protein, calmodulin, and proteasome 26 genes. As the proteins encoded by these genes are involved in the cytosolic route of antigen processing machinery, we next evaluated whether PAC and DOX in noncytotoxic concentrations changed expression of MHC class I antigen processing machinery (APM) components in three different colon cancer cell lines.

Results

Our results showed that PAC and DOX increased the intracellular expression of APM proteins, including calmodulin, LMP2, LMP7, TAP1 and tapasin. The biological significance of modulation of antigen processing and presentation proteins in tumor cells by ultra low nontoxic concentrations of chemotherapeutic drugs was revealed when non-treated and treated tumor cells were used as a source of tumor antigens for the generation of tumor-specific cytotoxic T cells (CTLs) in vitro. We demonstrated that (i) DCs that engulf tumor cells pretreated with noncytotoxic concentrations of chemotherapeutic agents induced CTLs with a higher cytotoxic potential than DCs loaded with nontreated tumor cells, and (ii) CTLs induced by tumor lysate-pulsed DCs killed live tumor cells more efficiently if these tumor cells were pretreated with noncytotoxic concentrations of chemotherapeutic drugs.

Conclusions

These results demonstrate that chemomodulation of human tumor cells with noncytotoxic concentrations of chemotherapeutic agents increases tumor immunogenicity and results in the generation of more efficient DC vaccines and CTLs, which can be used for cell-based anticancer immunotherapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. A.K. Nowak, R.A. Lake, B.W. Robinson, Combined chemoimmunotherapy of solid tumours: improving vaccines? Adv. Drug Deliv. Rev. 58, 975–990 (2006)

    Article  PubMed  CAS  Google Scholar 

  2. C. Menard, F. Martin, L. Apetoh, F. Bouyer, F. Ghiringhelli, Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity. Cancer Immunol. Immunother. 57, 1579–1587 (2008)

    Article  PubMed  CAS  Google Scholar 

  3. T. Zhang, D. Herlyn. Combination of active specific immunotherapy or adoptive antibody or lymphocyte immunotherapy with chemotherapy in the treatment of cancer. Cancer Immunol Immunother (2008).

  4. F. Ghiringhelli, N. Larmonier, E. Schmitt et al., CD4 + CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur. J. Immunol. 34, 336–344 (2004)

    Article  PubMed  CAS  Google Scholar 

  5. D. Hirschhorn-Cymerman, G.A. Rizzuto, T. Merghoub et al., OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis. J. Exp. Med. 206, 1103–1116 (2009)

    Article  PubMed  CAS  Google Scholar 

  6. H.J. Ko, Y.J. Kim, Y.S. Kim et al., A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model. Cancer Res. 67, 7477–7486 (2007)

    Article  PubMed  CAS  Google Scholar 

  7. S.K. Bunt, L. Yang, P. Sinha, V.K. Clements, J. Leips, S. Ostrand-Rosenberg, Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res. 67, 10019–10026 (2007)

    Article  PubMed  CAS  Google Scholar 

  8. E. Suzuki, V. Kapoor, A.S. Jassar, L.R. Kaiser, S.M. Albelda, Gemcitabine selectively eliminates splenic Gr-1+/CD11b + myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin. Cancer Res. 11, 6713–6721 (2005)

    Article  PubMed  CAS  Google Scholar 

  9. G.V. Shurin, I.L. Tourkova, R. Kaneno, M.R. Shurin, Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism. J. Immunol. 183, 137–144 (2009)

    Article  PubMed  CAS  Google Scholar 

  10. R. Kaneno, G.V. Shurin, I.L. Tourkova, M.R. Shurin, Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrations. J. Transl. Med. 7, 58 (2009)

    Article  PubMed  Google Scholar 

  11. H. Zhong, B. Han, I.L. Tourkova et al., Low-dose paclitaxel prior to intratumoral dendritic cell vaccine modulates intratumoral cytokine network and lung cancer growth. Clin. Cancer Res. 13, 5455–5462 (2007)

    Article  PubMed  CAS  Google Scholar 

  12. M. Obeid, A. Tesniere, F. Ghiringhelli et al., Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 13, 54–61 (2007)

    Article  PubMed  CAS  Google Scholar 

  13. T. Panaretakis, N. Joza, N. Modjtahedi et al., The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death. Cell Death Differ. 15, 1499–1509 (2008)

    Article  PubMed  CAS  Google Scholar 

  14. L. Apetoh, F. Ghiringhelli, A. Tesniere et al., Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 13, 1050–1059 (2007)

    Article  PubMed  CAS  Google Scholar 

  15. D.R. Green, T. Ferguson, L. Zitvogel, G. Kroemer, Immunogenic and tolerogenic cell death. Nat. Rev. 9, 353–363 (2009)

    Article  CAS  Google Scholar 

  16. C.J. Melief, Cancer immunotherapy by dendritic cells. Immunity 29, 372–383 (2008)

    Article  PubMed  CAS  Google Scholar 

  17. G.V. Shurin, I.L. Tourkova, M.R. Shurin, Low-dose chemotherapeutic agents regulate small Rho GTPase activity in dendritic cells. J. Immunother. 31, 491–499 (2008)

    Article  PubMed  CAS  Google Scholar 

  18. I.L. Tourkova, G.V. Shurin, G.S. Chatta et al., Restoration by IL-15 of MHC class I antigen-processing machinery in human dendritic cells inhibited by tumor-derived gangliosides. J. Immunol. 175, 3045–3052 (2005)

    PubMed  CAS  Google Scholar 

  19. T. Ogino, X. Wang, S. Ferrone, Modified flow cytometry and cell-ELISA methodology to detect HLA class I antigen processing machinery components in cytoplasm and endoplasmic reticulum. J. Immunol. Meth. 278, 33–44 (2003)

    Article  CAS  Google Scholar 

  20. H. Yu, M. Kortylewski, D. Pardoll, Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat. Rev. Immunol. 7, 41–51 (2007)

    Article  PubMed  CAS  Google Scholar 

  21. F. Moschella, E. Proietti, I. Capone, F. Belardelli, Combination strategies for enhancing the efficacy of immunotherapy in cancer patients. Ann. NY Acad. Sci. 1194, 169–178 (2010)

    Article  PubMed  CAS  Google Scholar 

  22. P.M. Kloetzel, The proteasome and MHC class I antigen processing. Biochim. Biophys. Acta 1695, 225–233 (2004)

    Article  PubMed  CAS  Google Scholar 

  23. B. Seliger, Molecular mechanisms of MHC class I abnormalities and APM components in human tumors. Cancer Immunol. Immunother. 57, 1719–1726 (2008)

    Article  PubMed  CAS  Google Scholar 

  24. M.G. Brown, J. Driscoll, J.J. Monaco, Structural and serological similarity of MHC-linked LMP and proteasome (multicatalytic proteinase) complexes. Nature 353, 355–357 (1991)

    Article  PubMed  CAS  Google Scholar 

  25. C.K. Martinez, J.J. Monaco, Homology of proteasome subunits to a major histocompatibility complex-linked LMP gene. Nature 353, 664–667 (1991)

    Article  PubMed  CAS  Google Scholar 

  26. V. Cerundolo, A. Kelly, T. Elliott, J. Trowsdale, A. Townsend, Genes encoded in the major histocompatibility complex affecting the generation of peptides for TAP transport. Eur. J. Immunol. 25, 554–562 (1995)

    Article  PubMed  CAS  Google Scholar 

  27. T.H. Hansen, M. Bouvier, MHC class I antigen presentation: learning from viral evasion strategies. Nat. Rev. 9, 503–513 (2009)

    Article  CAS  Google Scholar 

  28. G.V. Shurin, I.L. Tourkova, G.S. Chatta et al., Small rho GTPases regulate antigen presentation in dendritic cells. J. Immunol. 174, 3394–3400 (2005)

    PubMed  CAS  Google Scholar 

  29. E. Fonsatti, H.J. Nicolay, L. Sigalotti et al., Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2′-deoxycytidine in cutaneous melanoma: immunotherapeutic implications. Clin. Cancer Res. 13, 3333–3338 (2007)

    Article  PubMed  CAS  Google Scholar 

  30. A.N. Khan, C.J. Gregorie, T.B. Tomasi, Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells. Cancer Immunol. Immunother. 57, 647–654 (2008)

    Article  PubMed  CAS  Google Scholar 

  31. B. Seliger, U. Ritz, S. Ferrone, Molecular mechanisms of HLA class I antigen abnormalities following viral infection and transformation. Int. J. Cancer 118, 129–138 (2006)

    Article  PubMed  CAS  Google Scholar 

  32. N. Aptsiauri, T. Cabrera, R. Mendez, A. Garcia-Lora, F. Ruiz-Cabello, F. Garrido, Role of altered expression of HLA class I molecules in cancer progression. Adv. Exp. Med. Biol. 601, 123–131 (2007)

    Article  PubMed  Google Scholar 

  33. Y. Sun, A.J. Sijts, M. Song et al., Expression of the proteasome activator PA28 rescues the presentation of a cytotoxic T lymphocyte epitope on melanoma cells. Cancer Res. 62, 2875–2882 (2002)

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Microbiology and Immunology, Institute of Biosciences, São Paulo State University, Botucatu, SP, Brazil

    Ramon Kaneno

  2. Department of Pathology, University of Pittsburgh Medical Center, 5725 Presbyterian Hospital South Bldg, 200 Lothrop Street, Pittsburgh, PA, 15213, USA

    Galina V. Shurin, Hiam Naiditch, Jianhua Luo & Michael R. Shurin

  3. Universidade Estadual de Londrina, CESA, Londrina, PR, Brazil

    Felipe M. Kaneno

Authors
  1. Ramon Kaneno
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Galina V. Shurin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Felipe M. Kaneno
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hiam Naiditch
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jianhua Luo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Michael R. Shurin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael R. Shurin.

Additional information

This study was supported by NIH RO1 CA84270 (to Michael R. Shurin). Ramon Kaneno was supported by Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, CAPES – 0860-08-5, Brazil.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kaneno, R., Shurin, G.V., Kaneno, F.M. et al. Chemotherapeutic agents in low noncytotoxic concentrations increase immunogenicity of human colon cancer cells. Cell Oncol. 34, 97–106 (2011). https://doi.org/10.1007/s13402-010-0005-5

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13402-010-0005-5

Keywords

Search

Navigation